D-0144-2026 Class II Ongoing
FDA drug recall D-0144-2026 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Oct 28, 2025 and is designated Class II. Reason for recall: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 5, 2025
- Initiation Date
- Oct 28, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-046-88.
Reason for recall
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules.
Distribution pattern
U.S Nationwide.
Code information
Lot #: AD42468, Expiry: 2/28/2026; AD48705, Expiry: 4/30/2026.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0144-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026